NCT04276662View on ClinicalTrials.gov

Study of Single-dose DS-3201b in Participants With Hepatic Impairment

PHASE1CompletedINTERVENTIONAL

Enrollment

28

Participants

Timeline

Start Date

November 21, 2019

Primary Completion Date

February 23, 2021

Study Completion Date

February 23, 2021

Conditions

Hepatic Impairment

Interventions

DRUG

DS-3201b

1 dose of 50 mg DS-3201b

Trial Locations (3)

32809

Orlando Clinical Research Center, Orlando

33014

Clinical Pharmacology of Miami, LLC, Miami

78217

Worldwide Clinical Trials, San Antonio

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Daiichi Sankyo

INDUSTRY